Xtl Biopharma Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010854979
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | - | Capitalization | 5.28M 1.91B 7.23M |
---|---|---|---|---|---|
Net income 2022 | -1M -362M -1.37M | Net income 2023 | -1M -362M -1.37M | EV / Sales 2022 | - |
Net cash position 2022 | 3.72M 1.35B 5.09M | Net cash position 2023 | 2.01M 726M 2.75M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.72
x | P/E ratio 2023 |
-2.96
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 93.3% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Director/Board Member | 57 | 20-01-28 | |
Director/Board Member | 53 | 17-03-31 |
1st Jan change | Capi. | |
---|---|---|
+25.23% | 46.56B | |
+45.38% | 41.67B | |
+0.16% | 41.16B | |
+33.42% | 32.4B | |
+21.08% | 28.18B | |
-6.35% | 28.1B | |
+49.02% | 14.52B | |
+47.52% | 13.74B | |
+3.27% | 12.17B |